How Much Does NeuroBo Pharmaceuticals Inc. (NRBO) Pay Out In Dividends?

0
15
EDIT
EDIT

As of Friday close, NeuroBo Pharmaceuticals Inc.’s (NASDAQ:NRBO) stock was down -$6.9, moving down -27.80 percent to $17.92. The average number of shares traded per day over the past five days has been 4,571,591 shares. 2 times new highs have been achieved over the past 5 days, with a $9.64 gain in that time frame. In the last twenty days, the average volume was 1,144,557, while in the previous 50 days, it was 459,835.

Since last month, NRBO stock rose 49.22%. Shares of the company fell to $7.39 on 08/31/22, the lowest level in the past month. A 52-week high of $128.68 was reached on 09/13/22 after having rallying from a 52-week low of $7.39. Since the beginning of this year, NRBO’s stock price has dropped by -51.04% or -$18.68, and marked a new high 3 times. However, the stock has declined by -86.07% since its 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Financial Health

In the three months ended September 29, NeuroBo Pharmaceuticals Inc.’s quick ratio stood at 8.10, while its current ratio was 8.10, showing that the company is able to pay off its debt. Based on annual data, NRBO earned $14000.0 in gross profit and brought in $15.3 million in revenue.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected NeuroBo Pharmaceuticals Inc. to report -$0.18 quarterly earnings, the actual figure was -$0.16 per share, beating the consensus estimate by 11.10%. During the quarter, the company generated -$3.21 million in EBITDA. The liabilities of NeuroBo Pharmaceuticals Inc. were 1.25 million at the end of its most recent quarter ended September 29, and its total debt was $64000.0. The value of shareholders’ equity is $26.66 million.

Technical Picture

This quick technical analysis looks at NeuroBo Pharmaceuticals Inc.’s (NRBO) price momentum. With a historical volatility rate of 641.02%, the RSI 9-day stood at 53.79% on 16 September.

With respect to its five-day moving average, the current NeuroBo Pharmaceuticals Inc. price is up by +116.35% percent or $9.64. At present, NRBO shares trade +49.30% above its 20-day simple moving average and -22.02% percent below its 100-day simple moving average. However, the stock is currently trading approximately +19.44% above its SMA50 and -62.90% below its SMA200.

Stochastic coefficient K was 22.09% and Stochastic coefficient D was 29.52%, while ATR was 8.71. Given the Stochastic reading of 18.64% for the 14-day period, the RSI (14) reading has been calculated as 54.31%. As of today, the MACD Oscillator reading stands at 4.12, while the 14-day reading stands at 6.03.

Analyst Ratings

H.C. Wainwright launched its rating on NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) to a Buy in a note to investors on June 15, 2020. NeuroBo Pharmaceuticals Inc. (NRBO) has been rated Buy by analysts. According to 0 brokerage firms, NRBO is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate NeuroBo Pharmaceuticals Inc. stock as buy, with 1 recommending it as overweight.

With a median target price of $480.00, the current consensus forecast for the stock is $480.00 – $480.00. Based on these forecasts, analysts predict NeuroBo Pharmaceuticals Inc. (NRBO) will achieve an average price target of $480.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here